Showing results (211-220 of 277) with videos related to
Sort By:
Pageof 28
Haematologica|December 10, 2020
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trialCharlotte Pawlyn, David Cairns, Tom Menzies, et al.British Journal of Haematology|June 12, 2020
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myelomaCeri Bygrave, Charlotte Pawlyn, Faith Davies, et al.Scientific Reports|July 25, 2015
Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myelomaJonathan S Mitchell, David C Johnson, Kevin Litchfield, et al.Clinical Lymphoma, Myeloma & Leukemia|June 1, 2021
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI TrialSarah Bird, David Cairns, Tom Menzies, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetateAlison H M Reid, Gerhardt Attard, Daniel C Danila, et al.Nature Communications|November 25, 2016
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expressionNi Li, David C Johnson, Niels Weinhold, et al.European Journal of Cancer (Oxford, England : 1990)|January 4, 2023
Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022Christian Rothermundt, Dimosthenis Andreou, Jean-Yves Blay, et al.The Lancet. Oncology|November 3, 2023
A CT-based radiomics classification model for the prediction of histological type and tumour grade in retroperitoneal sarcoma (RADSARC-R): a retrospective multicohort analysisAmani Arthur, Matthew R Orton, Robby Emsley, et al.British Journal of Cancer|July 21, 2017
Active multiple myeloma suppresses and typically eliminates coexisting MGUSJohn P Campbell, Jennifer L J Heaney, Sankalp Pandya, et al.British Journal of Haematology|June 16, 2026
Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trialAndrew Hall, James Croft, Katrina Walker, et al.Pageof 28